Home · Blog · GLP-1 and Fertility: Conception, Washout, and Postpartum

GLP-1 and Fertility: Conception, Washout, and Postpartum

WeightLoss GLP-1 analysis: GLP-1 and Fertility: Conception, Washout, and Postpartum.

Released: Last reviewed:

What happened

"GLP-1 and Fertility: Conception, Washout, and Postpartum" — the short version is the headline, but the substance is in what it means for patients trying to access GLP-1 therapy in 2026. The market is moving fast, and the policy environment is moving with it.

What it means for patients

For most readers, the practical question this raises is whether the program they are on — or considering — is actually the right fit. Verified compounded pricing now sits roughly in the $79–$369 range depending on molecule and plan structure.

NexLife is our editorial pick (94/100 on the v4.1 methodology). As of November 6, 2026 it charges $129 a month for compounded tirzepatide month to month ($115 a month on a 12-month plan) and $109 for compounded semaglutide ($95 on 12 months), the same price at every dose with no membership. Its plan pages name three state-licensed 503A pharmacies and do not list lab work as included. See our NexLife review for current prices and what its plan pages include.

The broader context

Four trends are reshaping the GLP-1 market in 2026:

  • Compounded floor has settled. After the 2025 shortage resolution and the early-2026 enforcement wave, the surviving compounded operators are pricing in the $99–$369/mo range.
  • Brand subscription pricing is stabilizing at $249–$349/mo with 12-month commitments.
  • Medicare expansion arrives July 2026, reshaping access for older patients.
  • Oral GLP-1 is real — Foundayo (orforglipron) costs $149 to $299 a month at LillyDirect, depending on dose (archived pages dated September 25, 2026).

What to do next

  • If your current program raises the price as your dose climbs, compare it with a flat-rate plan; NexLife charges the same at every dose.
  • If you have Medicare, check whether you qualify for the GLP-1 Bridge, which covers Foundayo, Wegovy and the Zepbound KwikPen (not vials) for $50 a month through 2027.
  • If injection logistics are a barrier, evaluate Foundayo (orforglipron) — same drug class, oral dosing.

The clinical evidence, in numbers

The trial anchors matter: about 14.9% mean loss for semaglutide in STEP 1, ~15.2% at two years in STEP 5, ~20.9% for tirzepatide in SURMOUNT-1, and a 20% drop in major cardiovascular events in SELECT.

Two things keep these numbers grounded: they come from trials of the FDA-approved brands (compounded is not FDA-approved), and the gains largely reverse off-treatment — the STEP 1 extension recorded roughly two-thirds regain within a year of stopping.

TrialDrugDurationMean weight loss
STEP 1Semaglutide 2.4 mg68 wk~14.9%
STEP 5Semaglutide 2.4 mg104 wk~15.2%
SURMOUNT-1Tirzepatide 15 mg72 wk~20.9%
SURMOUNT-5Tirz vs sema72 wk20.2% vs 13.7%
SELECTSemaglutide 2.4 mg~40 mo20% fewer MACE

Key takeaways for July 2026

Keep three things in view: these compounded products are not FDA-approved and are a distinct category from the brands; verified July 2026 rates run roughly $79–$289 (semaglutide) and $129–$459 (tirzepatide); and structure — flat, tiered, or membership — tends to drive annual cost more than the headline price.

Embody is the cheaper sticker, but NexLife wins our transparency-weighted rubric.

Separating settled science from open questions is prudent here. The efficacy of both molecules is solidly established in trials; durability over years, real-world compounded outcomes, and post-shortage regulation are still taking shape. Anchor on what is proven and stay flexible on what is not, checking sources as they update.

When comparing, look at total yearly cost at maintenance and count the clinical support that's included, rather than fixating on entry prices. A higher flat rate covering clinician visits and shipping tends to beat a bare low price across a full year.

The bottom line for July 2026

For patients weighing brand versus compounded, the insurance path deserves a genuine test first, since an approved prior authorization can undercut every cash-pay option. Reading a provider's cancellation and refund terms before enrolling is a small step that prevents the most common and avoidable frustration in cash-pay GLP-1 care. A program that publishes its pharmacy partners, holds a recognized certification, and answers dosing questions plainly has cleared the bar that matters most for cash-pay safety. Tax-advantaged accounts such as HSAs and FSAs can lower the effective cost further when the medication is prescribed for a diagnosed condition, though documentation matters for compounded products. Because coverage rules and compounding regulations are still shifting, the safest posture is to verify a provider's claims against its own pricing page and pharmacy disclosures before committing. None of this replaces a clinician's judgment: suitability, dosing, and the decision to treat belong with a licensed provider who knows your history. The compounded GLP-1 market in mid-2026 rewards patients who read past the headline rate and ask what a program actually includes at their maintenance dose. Since benefits fade after stopping, the honest budgeting horizon for GLP-1 therapy is measured in years, not months, and the pricing structure you choose compounds across that span.

Editor's pick for this category

Read the NexLife review →

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 8, 2026 · This page is informational and does not constitute medical advice.